pennystocksupdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 02/05/2014 -- GTx, Inc. (NASDAQ:GTXI) reported EPS of -0.715. For the Current Fiscal year, the company is expected to report EPS of -0.67. For the Next Quarter and Next Year, the company is expected to report EPS of -0.12 and -0.37 respectively. At Current Market Price, GTXI is in distance of -7.45% from its 50-day Moving Average price of $1.7936 and -21.44% from its 200-day Moving Average price of $2.1131. GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss).
Is GTXI a Solid Investment at These Levels? Find Out Here
Shares of Medivation, Inc. (NASDAQ:MDVN) are trading at $74.45 and is +5.05% from its 50-day Moving Average price of $70.8679 and +20.71% from its 200-day Moving Average price of $61.6746. The average trading volume is 1176760 shares and its market capitalization is $5.618B. Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer.
How Should Investors Trade MDVN After Today’s Rally? Find Out Here
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is very active today and traded between $6.31 - 6.38 with total traded volume of 13579 shares. At a current price of 6.31, ADMP is -0.08 - -1.25% from the previous close of $6.39. Moreover, At Current Market Price, ADMP is in distance of -2.83% from its 50-day Moving Average price of $6.4941 and -8.52% from its 200-day Moving Average price of $6.8973. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc.operates through its wholly owned subsidiaries Cellegy Holdings, Inc., Adamis Corporation and Biosyn, Inc. Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc. (Adamis Viral) and Adamis Laboratories, Inc. (Adamis Labs).
How Should Investors Trade ADMP After The Recent Momentum? Find Out Here
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) is -0.33 - -0.48% from the previous close of $68.66. It traded between $67.90 - 68.43 with total traded volume of 106804 shares. Keep a close eye on RHHBY, as the stock has been showing unusual moves over the past weeks. At Current market price, RHHBY has recovered +26.82% from its 52-week Low of 53.88 and has Pulled back -4.90% from its 52-week high of 71.85. Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring.
Is RHHBY Showing Any Sign of Buy At The Current Market Price? Find Out Here
Neither Pennystocksupdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Adviser or broker dealer in any jurisdiction whatsoever and none of the information provided by Pennystocksupdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. Pennystocksupdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Pennystocksupdate.biz . Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.
Read full disclaimer: http://www.pennystocksupdate.biz/disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)